Malaria is a public health challenge that requires prompt treatment for those infected to make a full recovery. Treatment of malaria infection is to be started as soon as a diagnosis is confirmed. Antimalarial medications are administered to prevent and also to treat malaria. The type of medication used and the duration of therapy is dependent on the type of malaria-causing plasmodium species, the severity of the symptoms, geographical area where malaria infection occurred and the medication used to prevent malaria and whether there is pregnancy. Treatment of malaria from public health perspective is to reduce transmission of the infection to others, by reducing the infectious reservoir and to prevent the emergence and spread of resistance to antimalarial medicines. Medications used in the treatment of malaria infection come from the following five groups of chemical compounds: quinolines and aryl amino alcohols, antifolate, artemisinin derivatives, hydroxynaphthoquinones and antibacterial agents. The treatment of malaria is not initiated until the diagnosis has been established through laboratory testing. Artemisinin-based Combination Therapy (ACTs) has been used for the treatment of uncomplicated malaria. ACTs are also to enhance treatment and protect against the development of drug resistance. IV artesunate is used in the treatment of severe malaria, regardless of infecting species.

The leaf of Theobroma cacao L. is used in traditional medicine in Ghana for the treatment of malaria, yet, with no scientific evidence of its antimalarial property in animals. It was, therefore, studied to validate the antimalarial property in Plasmodium berghei-infected mice. Infected mice were treated with an aqueous extract of T. cacao leaf at different doses of 100, 200, and 400 mg/kg daily for four days. Parasitaemia was determined before treatment and 24 hours following the last dose of extract. The % reduction in parasitaemia and ED50 and ED90 of the extract were determined. Body weight, rectal temperature, and daily mortality of mice were also recorded. The extract had ED50 and ED90 of 242.20 ± 29.38 and 351.00 ± 29.52 mg/kg/day, respectively. Percentage parasitaemia suppression was significant for all doses. The extract at the maximum dose of 400 mg/kg body weight had the highest % parasitaemia suppression of 79.19%; mean survival time of 24.00 ± 2.19 days and median survival of 23 days; body weight increase of 3.82 ± 0.59; and the lowest body temperature reduction of 0.79 ± 0.11°C. T. cacao leaf extract showed an antimalarial property in P. berghei-infected mice. This reinforces the justification for the use of the plant material in treating malaria in Ghana.

No abstract